[{"address1": "55 University Ave.", "address2": "Suite 1003", "city": "Toronto", "state": "ON", "zip": "M5J 2H7", "country": "Canada", "website": "https://www.fsdpharma.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Zeeshan  Saeed", "age": 53, "title": "Founder, CEO, President & Executive Co-Chairman", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 222625, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anthony John Durkacz", "age": 47, "title": "Founder & Executive Co-Chairman", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 222625, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Donal  Carroll CPA", "age": 46, "title": "CFO & COO", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 225625, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nathan  Coyle CPA", "age": 42, "title": "Controller", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 178208, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lakshmi P. Kotra BPHARM, Ph.D.", "age": 52, "title": "CEO of Lucid & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 144724, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jason D. Sawyer", "title": "Head of Finance & Mergers and Acquisitions", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maryann  Adesso", "title": "Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Randell  Mack", "title": "President of FSD BioSciences", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrzej  Chruscinski M.D., Ph.D.", "title": "Vice President of Clinical & Scientific Affairs of Lucid", "fiscalYear": 2023, "totalPay": 110304, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin  Cassidy", "title": "Vice President of Quality-Lucid", "fiscalYear": 2023, "totalPay": 144822, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.69, "open": 5.75, "dayLow": 5.58, "dayHigh": 5.8575, "regularMarketPreviousClose": 5.69, "regularMarketOpen": 5.75, "regularMarketDayLow": 5.58, "regularMarketDayHigh": 5.8575, "beta": 0.828, "forwardPE": -0.72615385, "volume": 60655, "regularMarketVolume": 60655, "averageVolume": 528516, "averageVolume10days": 159630, "averageDailyVolume10Day": 159630, "bid": 5.31, "ask": 5.4, "bidSize": 100, "askSize": 100, "marketCap": 11758294, "fiftyTwoWeekLow": 3.5, "fiftyTwoWeekHigh": 97.5, "fiftyDayAverage": 4.47042, "twoHundredDayAverage": 24.747604, "currency": "USD", "enterpriseValue": 3906427, "floatShares": 1074158, "sharesOutstanding": 1856900, "sharesShort": 10086, "sharesShortPriorMonth": 116367, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0054, "heldPercentInsiders": 0.13735, "heldPercentInstitutions": 0.01497, "shortRatio": 0.2, "shortPercentOfFloat": 0.0057, "impliedSharesOutstanding": 2075970, "bookValue": 15.024, "priceToBook": 0.37699682, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -7469648, "trailingEps": -13.0, "forwardEps": -7.8, "lastSplitFactor": "1:65", "lastSplitDate": 1723680000, "enterpriseToEbitda": -0.388, "52WeekChange": -0.91198134, "SandP52WeekChange": 0.39389753, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "QNTM", "underlyingSymbol": "QNTM", "shortName": "Quantum Biopharma Ltd.", "longName": "Quantum BioPharma Ltd.", "firstTradeDateEpochUtc": 1528464600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f42facd1-8c36-3575-aad6-d7d2f4437719", "messageBoardId": "finmb_266208867", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.664, "targetHighPrice": 169.0, "targetLowPrice": 169.0, "targetMeanPrice": 169.0, "targetMedianPrice": 169.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 3328559, "totalCashPerShare": 2.559, "ebitda": -10064798, "totalDebt": 625196, "quickRatio": 1.961, "currentRatio": 1.987, "debtToEquity": 6.128, "returnOnAssets": -0.36116, "returnOnEquity": -0.63893, "freeCashflow": -9990220, "operatingCashflow": -5144110, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]